A practical reference on MOD GRF(1-29): what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-29. Anything still debated is marked as such rather than presented as settled.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
Smashburger IP Holder LLC, doing business as Smashburger (stylized SmashBURGER), is an American multinational fast-casual hamburger restaurant chain founded in Denver, Colorado. As of 2022, it has more than 227 corporate and franchise-owned restaurants in 35 U.S. states, the District of Columbia and 2 Canadian provinces. Founded in 2007 by Rick Schaden and Tom Ryan, the chain serves "smashed" burgers using a specialized process of cooking them on a flattop grill at a high heat. This technique originated in the Great Lakes region at pressed-chuck burger restaurants, and has been a staple there for decades. The method sears the burger for flavor. These are then topped with additional ingredients and can be customized. At one time, the chain offered unique burgers in each city where its restaurants were located. The menu also includes chicken, turkey and portobello sandwiches as well as french fries, sweet potato fries, fried pickles and other items. Some locations offer the Udi's gluten-free bun. The restaurant saw rapid growth after its first location opened in 2007 and it added several hundred locations within a few years, although a larger slowdown of the "better burger" industry saw it slow its size and expansion plans. Company leaders initially considered an IPO, but Philippine-based quick-service operator Jollibee Group bought a 40 percent stake in the company in 2015, at which time it was valued at $335 million. As of December 2018, Jollibee owns 100% of Smashburger.
=== Persistent infection === Most often, SeV infection initiates an apoptotic program in the host cells, which leads to the death of target cells without interrupting the life cycle of the virus. However, paramyxoviruses, including SeV, can cause persistent infection in primary cell cultures that does not kill cells or turn off cellular RNA transcription and translation. It has been demonstrated that mouse connective tissues cells (L-929) and hamster kidney fibroblasts (BHK-21) can become infected with Sendai virus and the infection can be persistent. The possibility of establishing a persistent viral infection was demonstrated in SeV-infected ovine fibroblasts.
Dolor (pain) Calor (heat) Rubor (redness) of the skin Tumor (swelling) Functio laesa (loss of function) The first four (classical signs) were described by Celsus (c. 30 BC–38 AD). Pain is due to the release of chemicals such as bradykinin and histamine that stimulate nerve endings. Heat and redness are due to increased blood flow at body core temperature to the inflamed site. Swelling is caused by accumulation of fluid. The fifth sign, loss of function, is believed to have been added later by Galen, Thomas Sydenham or Rudolf Virchow. Examples of loss of function include pain that inhibits mobility, severe swelling that prevents movement, having a worse sense of smell during a cold, or having difficulty breathing when bronchitis is present. Loss of function has multiple causes. Chronic inflammation often presents symptoms such as:
Sources: en.wikipedia.org
=== Commercial production === Industrial production of vitamin B12 is achieved through fermentation of selected microorganisms. As noted above, the completely synthetic laboratory synthesis of B12 was achieved by Robert Burns Woodward and Albert Eschenmoser in 1972, though this process has no commercial potential, requiring more than 70 steps and having a yield well below 0.01%.
Modafinil is commercially available in 100 mg and 200 mg oral tablet forms. Additionally, it is offered as the (R)-enantiomer, known as armodafinil, and as a prodrug named adrafinil. Armodafinil is available in 50, 150, 200, and 250 mg tablets. A 100 mg dose of modafinil has been said to be essentially equivalent to a 50 mg dose of armodafinil in terms of drug levels.
=== 22 February === The SAF and the Sudan Shield Forces claimed to have forced the RSF to retreat from the Soba neighbourhood of eastern Khartoum and retook the Al-Lulua and Al-Samra neighbourhoods southeast of the Soba Bridge connecting Khartoum's southern and eastern neighbourhoods with the rural areas of East Nile, adding that the 17 RSF militants were killed while nine vehicles were destroyed or captured.
Sources: en.wikipedia.org
== Precursors == Before the outbreak of World War II, Army commanders had recognized the inadequacy of heavy canned wet rations when employed for infantry marching on long patrols, especially in extreme environments such as mountain or jungle terrain. To this end, the Jungle ration was developed and briefly issued during early World War II. The Jungle ration was a dry, lightweight multi-component daily meal that could be stored in light waterproof bags, easily carried by a foot soldier, and which would not spoil when exposed to heat and humidity for an extended period of time. Importantly, the Jungle ration was specifically designed to provide an increased amount of dietary energy despite its lighter weight, ideal for a soldier operating in difficult jungle terrain on foot while carrying all of his equipment on his back. By all accounts the Jungle ration was successful; however, cost concerns led to its replacement, first by substitution of increasingly heavier and less expensive canned components, followed by complete discontinuance in 1943. After the war, U.S. Army logisticians again re-standardized field rations, eliminating all lightweight rations in favor of heavy canned wet rations such as the C-ration and the MCI. The overuse of heavy canned wet rations reached a ludicrous extreme during the early years of U.S. involvement in the Vietnam War, when American soldiers on extended infantry patrol were forced to stack their canned rations in socks to minimize weight and noise.
Its cavalry included 400 men from the Cape Mounted Riflemen, 600 men from the Cape Mounted Yeomanry (CMY), 200 riders from Kimberley Horse, as well as small units of scouts and African levies. Its infantry consisted of the Prince Alfred Volunteer Guards, Duke of Edinburgh's Volunteer Guards and First City Volunteer Rifles, each numbering 100 to 200 soldiers. The force also included three RML 7-pounder mountain guns and two 5.5-inch mortars. A total of 3,000 white and 1,000 African troops were involved in the campaign. The Basuto vastly outnumbered their adversaries, Lerotholi commanded 23,000 cavalry, of which 9,000 were concentrated in the Mafeteng District where most of the fighting took place. A part of the Basuto army was tasked with guarding Letsie's ancestral village of Morija. Masopha blockaded the garrison of 200 CMR soldiers at Maseru. He burned Maseru's main buildings in his first assault on the town, but further attacks proved less successful. In the north, Joel Molapo's attack on Hlotse was likewise repulsed and he initiated a siege. The magistracies at Mohale's Hoek and Quthing were abandoned by the Cape troops. The rebellion continued to spread across Basutoland, with clashes taking place across seven different fronts. The heavy casualties suffered by the Basuto during their frontal assaults caused them to increasingly adopt the tactics of the Boer Commando; employing ambushes and defending fortified positions. Their high mobility allowed them to engage their opponents only when they believed that conditions favored them and to quickly withdraw after firing.
small temporal RNA (stRNA) A subclass of microRNAs, originally described in nematodes, which regulate the timing of developmental events by binding to complementary sequences in the 3' untranslated regions of messenger RNAs and inhibiting their translation. In contrast to siRNAs, which serve similar purposes, stRNAs bind to their target mRNAs after the initiation of translation and without affecting mRNA stability, which makes it possible for the target mRNAs to resume translation at a later time.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.